Tissue penetration of antimicrobials: Difference between revisions

From IDWiki
Line 24: Line 24:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" | +
| style="text-align:center" | +
|
|Β±
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
Line 32: Line 32:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
|
|–
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" | +†
| style="text-align:center" | +†
Line 41: Line 41:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |–
| style="text-align:center" |–
|
|–
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
Line 57: Line 57:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
|
|Β±
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" | +†
| style="text-align:center" | +†
Line 73: Line 73:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" | +
| style="text-align:center" | +
|
|Β±
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
Line 95: Line 95:
| style="text-align:center" |–
| style="text-align:center" |–
|-
|-
|[[Carbapenems]]
| rowspan="2" |[[Carbapenems]]
|[[imipenem]]
|[[imipenem]]
| style="text-align:center" |
| style="text-align:center" |
Line 103: Line 103:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" | +
| style="text-align:center" | +
|-
|[[meropenem]]
|
| +
| +
|
|
| +
|-
|-
! colspan="8" |Antibiotics: Non-Ξ²-Lactams
! colspan="8" |Antibiotics: Non-Ξ²-Lactams
Line 186: Line 194:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" | +
| style="text-align:center" | +
|-
|[[Oxazolidinones]]
|[[linezolid]]
| +
| +
| +
|
|
|
|-
|-
|[[Rifamycins]]
|[[Rifamycins]]
Line 257: Line 274:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
|
| +
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
Line 266: Line 283:
| style="text-align:center" | +
| style="text-align:center" | +
| style="text-align:center" |
| style="text-align:center" |
|
|–
| style="text-align:center" |–
| style="text-align:center" |–
| style="text-align:center" |
| style="text-align:center" |
Line 275: Line 292:
!Blood
!Blood
!CNS
!CNS
!Vitreous
!
!Urine
!Urine
!Prostate
!Prostate

Revision as of 01:54, 7 March 2021

Summary

Class Antimicrobial Blood CNS Vitreous Urine Prostate Necrotic
Antibiotics: Ξ²-Lactams
Penicillins Ξ²-lactamase inhibitors –
ampicillin + Β± –
piperacillin-tazobactam – +†
Cephalosporins first-generation cephalosporins – – –
second-generation cephalosporins –
third-generation cephalosporins Β± +†
cefepime +
ceftazidime + Β± +
Cephamycins cephamycins –
cefoxitin –
Carbapenems imipenem +
meropenem + + +
Antibiotics: Non-Ξ²-Lactams
Aminoglycosides –
Chloramphenicol chloramphenicol +
Fluoroquinolones –? + +
Fosfomycin fosfomycin +
Lincosamides clindamycin – +
Lipopeptides daptomycin + – +
Macrolides macrolides – +
Nitrofurans nitrofurantoin – – + – –
Nitroimidazoles metronidazole +
Oxazolidinones linezolid + + +
Rifamycins rifampin +
Sulfonamides trimethoprim-sulfamethoxazole +
Tetracyclines tetracyclines – +
doxycycline + +
Antivirals
acyclovir / valacyclovir +
ganciclovir +
foscarnet
Antifungals
Azoles fluconazole + +
Echinocandins + – –
Class Antimicrobial Blood CNS Vitreous Urine Prostate Necrotic
  • † if inflammation present

Specific Tissues

Prostate

  • Poorly penetrated by most antibiotics
  • Penetration is higher with a high concentration gradient, high lipid solubility, low degree of ionization, high dissociation constant, low protein binding, and small molecular size
  • Fluoroquinolones are the mainstay of therapy, though there is increasing resistance
  • TMP-SMX often used, though conflicting data about its penetration into the prostate
  • Minocycline, doxycycline, and macrolides achieve high levels in the prostate but are rarely indicated for the causative organisms
  • Third-generation cephalosporins and carbapenems can be used
  • Piperacillin, aztreonam, imipenem, and some aminoglycosides are likely useful

Bone

  • Essentially all antibiotics achieve similar bone-to-serum levels, with the exception of oral Ξ²-lactams which nevertheless have no worse outcomes1

Eye

Class Antimicrobial Retinal Penetration Vitreal Penetration Ref
Antibiotics
penicillins ampicillin below MIC in non-inflamed rabbit eyes 2
amoxicillin 2% (below MIC) in non-inflamed rabbit eyes 2
piperacillin undetectable in inflamed human eyes 2
cephalosporins cefazolin above MIC in inflamed rabbit eyes 2
ceftriaxone 4% in non-inflamed human eyes 2
ceftazidime 30% in inflamed rabbit eyes 2
cefipime 8% in non-inflamed human eyes 2
carbapenems imipenem 8 to 10% in non-inflamed human eyes 2
meropenem 30% in non-inflamed human eyes 2
oxazolidinones linezolid 30 to 80% in non-inflamed human eyes 2
vancomycin above MIC in inflamed rabbit eyes 2
daptomycin 30% in inflamed human eyes 2
aminoglycosides amikacin below MIC in inflamed rabbit eyes 2
gentamicin below MIC in inflamed rabbit eyes 2
fluoroquinolones ciprofloxacin below MIC in non-inflamed human eyes 2
levofloxacin 30% but below MIC in non-inflamed human eyes 2
moxifloxacin 10 to 40% and above MIC in non-inflamed human eyes 2
Antifungals
azoles fluconazole 40 to 50% 40 to 50% 34
itraconazole 10% in inflamed eyes 4
posaconazole 20% in inflamed eyes 4
voriconazole 40 to 100% 4
flucytosine 40 to 100% 4
liposomal amphotericin B only detectable in inflamed eyes 4
echinocandins echinocandins very low penetration 4
micafungin excellent undetectable 34

References

  1. ^  Cornelia B. Landersdorfer, JΓΌrgen B. Bulitta, Martina Kinzig, Ulrike Holzgrabe, Fritz SΓΆrgel. Penetration of Antibacterials into Bone. Clinical Pharmacokinetics. 2009;48(2):89-124. doi:10.2165/00003088-200948020-00002.
  2. ^  L. Brockhaus, D. Goldblum, L. Eggenschwiler, S. Zimmerli, C. Marzolini. Revisiting systemic treatment of bacterial endophthalmitis: a review of intravitreal penetration of systemic antibiotics. Clinical Microbiology and Infection. 2019;25(11):1364-1369. doi:10.1016/j.cmi.2019.01.017.